Featured Article
An analysis of clinical data by researchers at Brigham and Women’s Hospital has found that radiofrequency (RF)-based ablation has a success rate of 85.7% treating atrial fibrillation (AF) one year after the procedure.
Precision Oncology Today
Magazine
Beginning a New Era of Precision Alzheimer’s Therapeutics
Alzheimer’s is a disease associated with aging and impacts almost seven million people in the U.S. over the age of 65, with women and Black or Hispanic populations disproportionately affected by the condition. Finding an effective treatment for Alzheimer’s disease has proved to be a long and difficult quest.
5 Startups With Proteomics Potential Attracting Investor Cash
Investor appetite is growing for startups that can make proteomics faster, cheaper, and more informative for use in precision medicine. Here are five proteomics...
Trending on Inside Precision Medicine
Study of Brain Related Genes Showcases Value of Diverse Biobanks
Diverse tissue-based biobank helps assess the impact of genetic ancestry on brain disorders like Alzheimer's in African Americans.
SHORE’d-up: Heart Transplant Rejection Diagnostic Outperforms Biopsies
For much of the past few decades, the standard protocol for centers around the country has been to routinely perform 15 to 20 heart biopsies to screen for graft rejection over the first few years after a heart transplant. That's why Kiran Kaur Khush, MD, professor of medicine at Stanford University, has been developing and testing a new, noninvasive molecular diagnostic.
Radiofrequency-Based Ablation Shows 85.7% Success Rate Treating Atrial Fibrillation
An analysis of clinical data by researchers at Brigham and Women’s Hospital has found that radiofrequency (RF)-based ablation has a success rate of 85.7% treating atrial fibrillation (AF) one year after the procedure.
